The findings support further clinical investigations into mTOR-targeting drugs to assess their potential benefits in DN management. Genes & Diseases publishes rigorously peer-reviewed and high ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway ...

Innovations in therapeutic strategies, coupled with a deeper understanding of breast cancer biology, will be essential for advancing personalized ...

While Rheb mutations also result in mTOR pathway hyperactivation, TSC is predominately caused by mutations in the TSC2 or TSC2 genes, which are key regulators of the mTOR pathway. So, PTI-125’s ...

Genprex (GNPX) announced that its research collaborators will present at the upcoming 2025 American Association for Cancer Research, or AACR, ...